GlobeNewswire by notified

Bavarian Nordic Enters Vaccine Supply Contract with the European Health Emergency Preparedness and Response Authority (HERA) in Response to Monkeypox Outbreak

Share
  • HERA has ordered 110,000 doses of the Company’s MVA-BN smallpox/monkeypox vaccine for donation to Member States
  • Deliveries will start immediately and will be completed during the next months
  • Company upgrades financial guidance for 2022

COPENHAGEN, Denmark, June 14, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Health Emergency Preparedness and Response Authority (HERA) has ordered 110,000 doses of MVA-BN smallpox/monkeypox vaccine, which will be made available to EU Member States, Norway and Iceland in response to the current monkeypox outbreak.

Established by the European Commission in September 2021, HERA’s purpose is to strengthen Europe’s ability to prevent, detect, and rapidly respond to cross-border health emergencies, by ensuring the development, manufacturing, procurement, and equitable distribution of key medical countermeasures.

Deliveries of vaccines to HERA will commence immediately and will be completed during the next months.

Paul Chaplin, President and CEO of Bavarian Nordic said: “We are pleased to enter an agreement with HERA on supplying our vaccine, thus helping to improve the EU readiness and response during the current outbreak of monkeypox throughout Europe. By now, there are registered cases of monkeypox in more than 20 European countries, and while we have already delivered significant quantities of our vaccine to some individual EU member states, the supply to HERA now enables a more integrated and coordinated approach across the entire EU, in line with HERA’s mission.”

As a consequence of the order from HERA, and other smaller orders, Bavarian Nordic raises its expectations for the financial results for 2022 with revenue now expected to be between DKK 1,900 and 2,100 million (previously between DKK 1,800 and 2,000 million), EBITDA expectations raised to a loss between DKK 600 and 800 million (previously a loss between DKK 700 and 900 million) and cash and cash equivalents at year-end now between DKK 1,500 and 1,700 million (previously between DKK 1,400 and 1,600 million). The guidance reflects the significant investments in research and development being made in 2022 to advance the Company’s two lead product candidates: a vaccine against respiratory syncytial virus (RSV) and a booster vaccine against COVID-19 into Phase 3 clinical trials.

About the smallpox/monkeypox vaccine
MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic (marketed as IMVANEX® in Europe, JYNNEOS® in the U.S. and IMVAMUNE® in Canada) is a non-replicating smallpox vaccine developed in collaboration with the U.S. government to ensure supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines. The vaccine was approved by the European Commission in 2013 for immunization against smallpox in adults aged 18 years and older and has subsequently gained regulatory approvals in Canada and the U.S. where the approval has been extended to include the monkeypox indication as the only vaccine having obtained this to-date.

Bavarian Nordic has ongoing supply contracts with USA and Canada and has delivered the vaccine to a number of undisclosed countries globally as part of their national biological preparedness. In recent years, smaller quantities of the vaccine have been supplied in response to sporadic cases of monkeypox. During the ongoing 2022 outbreak of monkeypox, Bavarian Nordic has worked with several governments to fulfil the immediate demand for the vaccine through a number of supply agreements and is working to secure manufacturing of vaccines to fulfil the demand in the medium- to long term.

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is also approved for protection against smallpox and monkeypox in Canada, and as a smallpox vaccine in Europe. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Company Announcement no. 24 / 2022

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Arcoma vinner viktig upphandling i Finland. (MAR)27.6.2022 13:00:00 CEST | Pressemelding

2022-06-27 PRESSRELEASE Arcoma vinner viktig upphandling i Finland. Arcoma AB har vunnit viktig upphandlingpå upp till 6Arcoma Precision i5-system till ”HUS Medical Imaging Center” i Finland.Tre av systemen kommer att installeras under 2022 och kontraktet har en option på ytterligare tre system för installation under 2023. Det totala ordervärdet är upp till cirka 7,5MSek, beroende på tillval och optioner. Upphandlingen är vunnen av Lifemed Medical Systems som är Arcomas distributör och samarbetspartner i Finland och slutkunden är ”HUS Medical Imaging Center” som är en del av Helsingfors universitetssjukhus. "Vi är mycket glada över denna möjlighet att leverera dessa system till HUS, tillsammans med vår partner Arcoma. Ergonomi, patientsäkerhet och bra bildkvalitet var nyckelfaktorerna i detta anbud och Precision i5 är en perfekt lösning för att möta dessa behov ”, säger Mikko Isoviita, Sales Manager Lifemed Medical Systems. "Det är mycket glädjande att vi genom Lifemed vunnit denna upp

Arcoma wins important procurement in Finland. (MAR)27.6.2022 13:00:00 CEST | Press release

2022-06-27 PRESSRELEASE Arcoma wins important procurement in Finland. Arcoma AB has won important procurement of up to 6 Arcoma Precision i5 systems to “HUS Medical Imaging Center” in Finland. Three of the systems will be installed in 2022 and the contract has an option for three more systems for installation in 2023. The total order value is up to approximately SEK 7.5 million, depending on options. The procurement was won by Lifemed Medical Systems, which is Arcoma's distributor and partner in Finland, and the end customer is the “HUS Medical Imaging Center”, which is part of Helsinki University Hospital. "We are very pleased for this opportunity to supply these systems to HUS, together with our long-term partner Arcoma. Ergonomics, patient safety and good image quality were they key factors in this tender and Precision i5 is a perfect solution to address these needs”, says Mikko Isoviita, Sales Manager Lifemed Medical Systems. "It is great that we through Lifemed have won this procu

Change in Aspo’s Group Executive Committee27.6.2022 10:20:00 CEST | Press release

Aspo Plc Stock exchange release June 27, 2022 at 11:20 a.m. Change in Aspo’s Group Executive Committee Heli Arantola, Managing Director of Aspo’s subsidiary Leipurin, has resigned to join another company. Arantola will leave the company in December at the latest, and the process of selecting her successor has begun. “I thank Heli for her excellent contribution to the modernization of Leipurin and transforming the company in the rapidly changing bakery and food industry. I wish her the best of luck in her future endeavors,” says Rolf Jansson, CEO of Aspo Group. Aspo Plc Rolf Jansson CEO Further information, please contact: Rolf Jansson, CEO, Aspo Plc, +358 400 600 264, rolf.jansson@aspo.com DISTRIBUTION: Nasdaq Helsinki Key media www.aspo.com Aspo creates value by owning and developing business operations sustainably and in the long term. Our companies aim to be market leaders in their sectors. They are responsible for their own operations, customer relationships and the development of

Cool Company Ltd. – Mandatory Notification Of Trade27.6.2022 10:17:48 CEST | Press release

EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 24 June 2022 acquired 7,035 shares in the Company at a price of NOK 89.307527 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,598,523 shares in the Company, equivalent to 38.99% of the Company’s shares. Please see attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Primary insider notification form

Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme27.6.2022 08:45:00 CEST | Press release

Company Announcement No. 43/2022 Copenhagen, 27 June 2022 Transactions in connection with share buy-back programme On 19 May 2022, Scandinavian Tobacco Group A/S announced that the share buy-back programme that was initiated 9 March 2022 was increased to an aggregated value of up to DKK 1,000 million. The purpose of the programme is to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. Part of the buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Another part of the share buy-back programme is conducted as a directed buy-back from Chr. Augustinus Fabrikker Aktieselskab and C.W. Obel A/S as further described in company announcement no. 35/2022. The share buy-back programme will end no later than 28 February 2023. The